Up to 70% of women develop uterine fibroids1, often without symptoms. For those affected by pain, heavy bleeding, or infertility, laparoscopic myomectomy is the preferred treatment. U-SURGAR™ revolutionizes this approach by using augmented reality to visualize critical uterine structures in real-time.
Gynecologic Surgeon Dr. Olivier Donnez
from ELSAN Polyclinique Urbain V in Avignon, discusses the benefits of SURGAR for his practice and patient care.
Intuitive and user-friendly, surgical teams can go from hands-on training to live procedures in a single day.
Engineered for immediate use with no workflow disruption.
Effortlessly integrates with any laparoscope or surgical robot, no special hardware or workflow changes required.
Myomectomy Like Never Before
2,3,4,5,6
Optimized Surgical Planning
Leverage patient-specific 3D models for greater confidence before entering the OR
Enhanced Localization of Fibroids and Adenomyomas
Accurately visualize and target deep or obscured tumors with precision, while preserving surrounding critical anatomical structures
Reduced Mental Workload
Augmented reality supports decision-making and spatial orientation in real-time
Accelerated Laparoscopic Learning Curve
Rapidly gain proficiency in minimally invasive myomectomy techniques
Real-Time Tracking of Internal Structures
Maintain continuous awareness of critical anatomy for optimal surgical gestures
1 Giuliani E, AsSanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020 Apr;149(1):3–9. doi:10.1002/ijgo.13102
2 Chauvet P, Bourdel N, Calvet L, Magnin B, Teluob G, Canis M, Bartoli A. Augmented reality with diffusion tensor imaging and tractography during laparoscopic myomectomies. J Minim Invasive Gynecol. 2020;27(4):973‑976. doi:10.1016/j.jmig.2019.11.007
3 Bourdel N, Chauvet P, Calvet L, Magnin B, Bartoli A, Canis M. Use of augmented reality in gynecologic surgery to visualize adenomyomas. J Minim Invasive Gynecol. 2019;26(6):1177–1180. doi:10.1016/j.jmig.2019.04.003
4 Chauvet P, Collins T, Debize C, NovaisGameiro L, Pereira B, Bartoli A, et al. Augmented reality in a tumor resection model. Surg Endosc. 2018;32(3):1192–1201. doi:10.1007/s00464-017-5791-7
5 Bourdel N, Collins T, Pizarro D, Debize C, Grémeau AS, Bartoli A, Canis M. Use of augmented reality in laparoscopic gynecology to visualize myomas. Fertil Steril. 2017;107(3):737–739. doi:10.1016/j.fertnstert.2016.12.016
6 Nicolas Bourdel, Toby Collins, Daniel Pizarro, Adrien Bartoli, David Da Ines, Bruno Perreira , Michel Canis. Augmented reality in gynecologic surgery: evaluation of potential benefits for myomectomy in an experimental uterine model. Surg Endosc2017 Jan;31(1):456-461.: 10.1007/s00464-016-4932-8. Epub 2016 Apr 29.
Indications for Use
U-SURGAR™ device is indicated for intrauterine myomas (FIGO 2, 3, 4, and 5) and adenomyomas in adult patients (ages 18-84) who can undergo preoperative MRI imaging and laparoscopic surgery. It is suitable for one or multiple myomas and adenomyomas measuring up to 8 cm.
U-SURGAR™ Software Suite:
U-SURGAR™ Hardware:
SURGAR-Platform is a medical device accessory intended to be used to make the video stream of the camera used during surgery available to augmented reality software. SURGAR- Platform also allows to interact and display the software interface.
U-SURGAR™ safety has been demonstrated through a clinical trial registered on ClinicalTrials.gov (ID: NCT06067971).
U-SURGAR™ is a CE-marked medical device. It is not currently FDA-cleared for use in the United States.
